Dengue Fever Swept Southeast Asia in 2013 and in February 2016 Sanofi Pasteur, the vaccines division of France’s Sanofi SA, made Dengvaxia, its vaccine for dengue fever, widely available in the Philippines. Sanofi said the vaccine had later been launched in ten other countries: Brazil, Mexico, Costa Rica, Indonesia, Guatemala, Salvador, Peru, Singapore, Paraguay and Thailand.
Dengvaxia was said to have been recommended for use by the World Health Organization in April 2016 – but WHO denies this.
In a July report, the World Health Organization noted that the vaccination “may be ineffective or may theoretically increase the future risk of hospitalized or severe dengue illness” in those who have not had dengue at the time of vaccination.
After a fast-track approval process more than 730,000 people, mostly children older than nine, were given the vaccine, manufactured by the vaccinations division of French pharma giant Sanofi SA.
However, Jake Maxwell Watts, writing in the Wall Street Journal on December 4th, reports that the Philippines has suspended the Dengvaxia dengue fever vaccine. An investigation has been launched, after evidence showed it could worsen symptoms in some cases.
Representative of Paris based pharmaceutical company Sanofi-Pasteur, Thomas Triumphe Head for Asia Pacific, answers questions during the senate inquiry on the Dengvaxia vaccine
Sanofi said new data found the vaccine was effective for people who had already had dengue, but not for those who hadn’t. Regulators have now been asked to change the vaccine label to recommend that people don’t take the vaccine if they haven’t been infected previously to avoid developing a more severe form of the disease.
The government has suspended its vaccination program. Though no deaths or cases of severe dengue have been definitely linked to the vaccine, some politicians have pointed to cases of children who have died since receiving it.
Philippine Health Secretary Francisco Duque III told local media that the government would assess responsibility for the vaccine, which was approved under the previous administration, and consider charges against its manufacturer.
o
Recent Comments